氟伏沙明与安慰剂对有症状COVID-19门诊患者临床恶化的随机临床试验
该双盲随机远程临床试验纳入152例症状出现7天内、血氧饱和度≥92%的非住院COVID-19成人患者,比较氟伏沙明100mg每日三次与安慰剂。结论为氟伏沙明可能降低临床恶化风险,但样本量小、随访短,需更大规模试验确认。
要点
- 氟伏沙明组15天内临床恶化为0/80,安慰剂组为6/72。
- 样本量小、随访短,尚不能确定临床疗效。
核心结论
- 在有症状的COVID-19成人门诊患者中,与安慰剂相比,氟伏沙明治疗者15天内临床恶化的可能性更低。
研究设计与样本
- 双盲、随机、完全远程(无接触)临床试验,比较氟伏沙明与安慰剂。
- 纳入152例社区居住、非住院、确诊SARS-CoV-2感染、症状出现7天内且血氧饱和度≥92%的成人。
- 2020年4月10日至8月5日从圣路易斯大都市区(密苏里州和伊利诺伊州)入组,最终随访日期2020年9月19日。
- 随机分配接受氟伏沙明100mg每日三次(n=80)或安慰剂(n=72),疗程15天。
主要发现
- 152例随机患者平均(SD)年龄46(13)岁,女性109例(72%),115例(76%)完成试验。
- 氟伏沙明组发生1例严重不良事件和11例其他不良事件,安慰剂组发生6例严重不良事件和12例其他不良事件。
关键数值与推荐
- 主要结局为随机化后15天内临床恶化,需同时满足:气短或因气短/肺炎住院;室内空气下血氧饱和度<92%或需补充氧气使血氧饱和度≥92%。
临床怎么用
- 该初步研究提示氟伏沙明可能降低有症状COVID-19门诊患者15天内临床恶化风险。
- 因样本量小和随访短,临床 efficacy 的确定需更大规模随机试验及更明确结局指标。
局限性
- 样本量小。
- 随访持续时间短。
- 需更大规模随机试验以确定临床疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the σ-1 receptor, which regulates cytokine production. OBJECTIVE: To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was September 19, 2020. INTERVENTIONS: Participants were randomly assigned to receive 100 mg of fluvoxamine (n = 80) or placebo (n = 72) 3 times daily for 15 days. MAIN OUTCOMES AND MEASURES: The primary outcome was clinical deterioration within 15 days of randomization defined by meeting both criteria of (1) shortness of breath or hospitalization for shortness of breath or pneumonia and (2) oxygen saturation less than 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater. RESULTS: Of 152 patients who were randomized (mean [SD] age, 46 [13] years; 109 [72%] women), 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. CONCLUSIONS AND RELEVANCE: In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. However, the study is limited by a small sample size and short follow-up duration, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04342663.
引用
- Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 33180097. doi:10.1001/jama.2020.22760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。